Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.
Launched by NICOSIA GENERAL HOSPITAL · May 21, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of certain dietary supplements on patients who have undergone coronary artery bypass grafting (CABG), a surgery that helps improve blood flow to the heart. The trial aims to see if adding Vitamin C, Omega-3 fatty acids (found in fish oil), lignin (a type of dietary fiber), and lactulose (a substance that supports gut health) to the usual medications after surgery can help improve patients' recovery and overall well-being.
To participate in this trial, you need to be between 40 and 80 years old, have coronary artery disease, and be mentally clear, meaning you can understand what the study involves. If you qualify and choose to join, you will be randomly assigned to either receive the supplements along with your regular medications or to just take your usual medications. The study will track your health and recovery over about six months to see how the supplements may help. It’s important to note that participants cannot have certain medical conditions or be taking specific medications that could interfere with the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The subjects will be people 40-80 years old, with coronary artery disease, and mental clarity who will undergo Coronary Aortic Bypass (CABG) in our clinic (Public Cardiothoracic Surgery clinic in Nicosia General Hospital) and will be randomized into 2 groups (intervention group and control group).
- • Signed consent form
- • Ability to adhere to the protocol
- Exclusion Criteria:
- • Any psychiatric, neurological or motor disorder.
- • Hypersensitivity to the components of the supplement.
- • Combined Cardiac Surgery other than CABG and valve or aortic
- • Concurrent participation in other clinical trials.
- • Previous use of any probiotics, prebiotics, adsorbent dietary supplements, Vitamin C and/or Omega 3 fatty acids.
About Nicosia General Hospital
Nicosia General Hospital is a leading healthcare institution in Cyprus, dedicated to advancing medical research and improving patient outcomes. As a clinical trial sponsor, the hospital is committed to conducting high-quality, ethically sound research that adheres to international standards. With a team of experienced researchers and healthcare professionals, Nicosia General Hospital focuses on a wide range of therapeutic areas, aiming to contribute valuable insights to the medical community. The institution prioritizes patient safety and welfare throughout the trial process, ensuring transparency and adherence to regulatory guidelines. Through its clinical trials, Nicosia General Hospital strives to innovate and enhance treatment options for various health conditions, ultimately benefiting patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Strovolos, Nicosia, Cyprus
Patients applied
Trial Officials
Elpidoforos S. Soteriades, MD, Ass Prof
Study Chair
Open University of Cyprus
Athanasios D. Athanasiou, MD, MSc, MPA
Principal Investigator
Nicosia General Hospital
Elpidoforos S. Soteriades, MD, Ass Prof
Study Director
Open University of Cyprus
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported